Patent: 10,220,075

✉ Email this page to a colleague

Summary for Patent: 10,220,075

Scope and claims summary:

Title:	Amine pegylation methods for the preparation of site-specific protein conjugates
Abstract:	Examples include a method of making a protein-PEG conjugate. The method may include providing an aqueous protein solution. The aqueous protein solution may include a protein, a pH buffer, and a chelating agent. The chelating agent may be chosen from the group consisting of an aminopolycarboxylic acid, a hydroxyaminocarboxylic acid, an N-substituted glycine, 2-(2-amino-2-oxocthyl) aminoethane sulfonic acid (BES), and deferoxamine (DEF). The method may also include introducing sodium cyanoborohydride and a methoxy polyethylene glycol aldehyde to the aqueous protein solution. The sodium cyanoborohydride in the methoxy polyethylene glycol aldehyde may have a molar ratio ranging from about 5:1 to about 1.5:1. The method may further include reacting the methoxy polyethylene glycol aldehyde with the protein to form the protein-PEG conjugate. The pH buffer may maintain a pH of the aqueous protein solution ranging from 4.0 to 4.4 during the reaction.
Inventor(s):	Rosendahl; Mary S. (Broomfield, CO), Mantripragada; Sankaram B. (Windsor, CO)
Assignee:	REZOLUTE, INC. (Louisville, CO)
Application Number:	15/158,898
Patent Claims:	see list of patent claims

Details for Patent 10,220,075

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	⤷ Subscribe	2034-12-02
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	⤷ Subscribe	2034-12-02
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	⤷ Subscribe	2034-12-02
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994	⤷ Subscribe	2034-12-02
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018	⤷ Subscribe	2034-12-02
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 25, 1991	⤷ Subscribe	2034-12-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.